ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 With Cyclotron Produced 68Ga Utilizing the QUANTM Irradiation System™ and Solid Targets

ARTMS Inc. (ARTMS) and Isotopia Molecular Imaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (⁶⁸Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005044/en/

The specially designed Prostate-Specific Membrane Antigen (PSMA) kit for the preparation of ⁶⁸Ga-PSMA-11 (a radiopharmaceutical targeting PSMA for the imaging of prostate cancer using Positron Emission Tomography (PET)) was radiolabeled with high activity cyclotron produced ⁶⁸Ga following irradiation times of less than two hours. The Isotopia kit was radiolabeled with between 500 mCi and just over 2900 mCi of ⁶⁸Ga following multiple successful ⁶⁸Ga production runs utilizing the QIS™ and ARTMS’ high performance ⁶⁸Zn solid targets. The resultant product demonstrated 6-hour stability and radiochemical purity, which met or exceeded all regulatory standards. Cyclotron produced ⁶⁸Ga combined with a kit solution will give radiopharmacies near unlimited access to this diagnostic product and a cost effective solution.

“The demand for ⁶⁸Ga radiolabeled products will soon exceed the supply coming from ⁶⁸Ge/⁶⁸Ga generators. ARTMS’ QUANTM Irradiation System™ (QIS™) allows for the high activity and high quality ⁶⁸Ga production the Molecular Imaging community requires to properly serve their patients. The QIS™’ multiple-curie per hour ⁶⁸Ga production is one of the few true game changers I have seen during my career in Nuclear Medicine. We are very excited to bring on-demand ⁶⁸Ga doses to clinicians and patients in collaboration with our partners,” says Charles S. Conroy, Chief Executive Officer of ARTMS.

“Isotopia is focused on developing diagnostic and therapeutic tools that best serve our patients. We see ⁶⁸Ga as a better diagnostic tool to pair with Lu177 treatments. Isotopia’s high activity PSMA “kit” is a major step forward in how the global imaging community diagnoses prostate cancer. Multi-dose vial preparation will allow pharmacies to provide unit doses and allow clinicians to image patients with little to no restrictions. In addition, a 5 minute preparation and more than 95% radiochemical purity will enhance efficiency and save the radiopharmacies time and money. We aim to keep introducing to the market kit-based solutions for 50 and 100mCi Generators, cyclotron produced ⁶⁸Ga, and Lu177 labeling,” says Dr. Eli Shalom, CEO of Isotopia Molecular Imaging.

ARTMS recently announced the approval for its cyclotron produced ^99mTc product by Health Canada. ARTMS will continue the development of cyclotron-based products including ⁶⁸Ga with a focus on optimizing production potential and satisfying regulatory requirements for use in radiopharmaceutical kits.

About Prostate Cancer
Prostate cancer is the fourth most common cancer worldwide. In 2018, 1.3 million men were diagnosed with prostate cancer for the first time. Despite advances in treatments, prostate cancer still accounts for a significant number of deaths. In 2018, more than 365,000 men died from the disease. Rates of diagnosis are increasing, and the highest levels of prostate cancer are found in the US, Europe, Australia, and New Zealand.

About ARTMS
Based in Vancouver, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System™ (QIS™), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (⁶⁸Ga), zirconium-89 (⁸⁹Zr), technetium-99m (^99mTc) and copper-64 (⁶⁴Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.

For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter @Quantm99 and LinkedIn and visit http://www.artms.ca/.

About Isotopia
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and some of Israel's leading scientists in the field of radiopharmaceuticals. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers, and physicists. The experienced Isotopia team, together with its radio-nuclear pharmacy, cyclotron facility, ¹⁷⁷Lu production site and sterile manufacturing, are a well-established platform for development. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

For more information on Isotopia, please visit www.isotopia.co.il.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005044/en/

Contact information

ARTMS Corporate
Charles S. Conroy R.Ph, MBA
ARTMS, Inc.
Chief Executive Officer
conroy@artms.ca

ARTMS Business
Doug Gentilcore
ARTMS, Inc.
Chief Commercial Officer
gentilcore@artms.ca

Isotopia Corporate
Dr. Eli Shalom, PhD
Isotopia Molecular Imaging Limited
Chief Executive Officer
EShalom@isotopia.co.il

Isotopia Business
Keren Moshkoviz
Isotopia Molecular Imaging Limited
Director of Business Development
KMoshkoviz@isotopia.co.il